Published in Breast Cancer Res Treat on December 01, 2003
Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol (2011) 4.12
Immunotoxins for targeted cancer therapy. AAPS J (2006) 1.86
Cutaneous metastases of visceral tumours: a review. J Cancer Res Clin Oncol (2008) 1.45
Toxin-based therapeutic approaches. Toxins (Basel) (2010) 1.00
Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies. Oncogene (2013) 0.99
Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res (2005) 0.98
A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck. Drug Des Devel Ther (2009) 0.93
A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients. Drug Des Devel Ther (2010) 0.92
Immunogenicity of therapeutic recombinant immunotoxins. Immunol Rev (2016) 0.88
Intracellular Acidosis Promotes Mitochondrial Apoptosis Pathway: Role of EMMPRIN Down-regulation via Specific Single-chain Fv Intrabody. J Cancer (2015) 0.83
Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems. J Transl Med (2006) 0.81
A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells. Melanoma Res (2008) 0.80
Challenging the roles of CD44 and lipolysis stimulated lipoprotein receptor in conveying Clostridium perfringens iota toxin cytotoxicity in breast cancer. Mol Cancer (2014) 0.78
Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anti-Cancer Immunity. Cancer Immunol Res (2017) 0.77
Treatment of solid tumors with immunotoxins. Breast Cancer Res (2005) 0.75
Clinical targeting recombinant immunotoxins for cancer therapy. Onco Targets Ther (2017) 0.75
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2009) 7.21
Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol (2013) 4.28
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med (2012) 4.24
miR-212 and miR-132 are required for epithelial stromal interactions necessary for mouse mammary gland development. Nat Genet (2010) 4.06
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol (2007) 4.00
Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol (2013) 3.92
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol (2006) 3.52
Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol (2011) 3.45
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol (2008) 2.88
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene (2003) 2.84
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J (2003) 2.81
A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res (2012) 2.78
Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol (2007) 2.76
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol (2012) 2.72
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol (2005) 2.70
Identification of high risk breast-cancer patients by gene expression profiling. Lancet (2002) 2.67
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res (2010) 2.66
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol (2010) 2.54
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A (2013) 2.47
NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res (2006) 2.44
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol (2008) 2.43
Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol (2012) 2.38
A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res (2011) 2.26
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res (2009) 2.26
Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev (2006) 2.10
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A (2003) 2.09
Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer (2006) 2.04
Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat (2007) 2.01
Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer (2012) 1.91
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol (2011) 1.83
International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol (2003) 1.83
A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. Clin Cancer Res (2012) 1.83
STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes. Sci Signal (2014) 1.79
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat (2010) 1.73
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol (2010) 1.71
Preventive therapy for breast cancer: a consensus statement. Lancet Oncol (2011) 1.69
Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study. Onkologie (2007) 1.60
Breast cancer in the elderly. J Clin Oncol (2007) 1.60
HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J (2003) 1.59
Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res (2007) 1.58
T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing. Blood (2012) 1.55
Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer (2005) 1.54
Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance. Breast Cancer Res Treat (2011) 1.53
Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A (2012) 1.51
Limited relevance of the CHEK2 gene in hereditary breast cancer. Int J Cancer (2004) 1.49
Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene (2002) 1.48
Locoregional treatment of primary breast cancer: consensus recommendations from an International Expert Panel. Cancer (2010) 1.47
Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res (2002) 1.46
Trastuzumab single-drug therapy after failure of cytotoxic treatment for metastatic breast cancer. Onkologie (2010) 1.45
Phase II STUdy with 3rd- or 4th-line bendamustine (flat dose) therapy in patients with metastatic breast cancer. Onkologie (2009) 1.44
Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. J Immunol (2006) 1.43
Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer (2005) 1.42
The coactivator of transcription CREB-binding protein interacts preferentially with the glycosylated form of Stat5. J Biol Chem (2003) 1.42
In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest (2006) 1.41
Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat (2007) 1.41
Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate (2004) 1.40
Marathon run under chemotherapy: is it possible? Onkologie (2011) 1.40
Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther (2009) 1.40
Data-driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer. Breast Cancer Res Treat (2009) 1.38
Overexpression and forced activation of stat5 in mammary gland of transgenic mice promotes cellular proliferation, enhances differentiation, and delays postlactational apoptosis. Mol Cancer Res (2002) 1.38
CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood (2005) 1.38
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial. PLoS One (2013) 1.34
Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist (2002) 1.33
Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res (2005) 1.33
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat (2011) 1.32
Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res (2009) 1.32
Identification of cancer/testis genes by database mining and mRNA expression analysis. Int J Cancer (2002) 1.31
Temporal expression of adhesion factors and activity of global regulators during establishment of Staphylococcus aureus nasal colonization. J Infect Dis (2010) 1.30
Evidence and consensus-based German guidelines for the management of analgesia, sedation and delirium in intensive care--short version. Ger Med Sci (2010) 1.30
Docetaxel-related side effects and their management. Eur J Oncol Nurs (2009) 1.29
LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immun (2007) 1.28
Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother (2007) 1.27
The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res (2010) 1.25
Stress, genes and the mechanism of programming the brain for later life. Neurosci Biobehav Rev (2004) 1.24
Mammary epithelial reconstitution with gene-modified stem cells assigns roles to Stat5 in luminal alveolar cell fate decisions, differentiation, involution, and mammary tumor formation. Stem Cells (2010) 1.23
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer (2006) 1.23
Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst (2013) 1.21
An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res (2010) 1.17
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. Mol Ther Nucleic Acids (2013) 1.16
Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. Eur J Cancer (2011) 1.16
NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med (2012) 1.16
Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst (2004) 1.15
DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. J Angiogenes Res (2009) 1.15
Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. J Nucl Med (2002) 1.15
Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res (2002) 1.15